Home > Executive Order

AI Summary: This is a policy document - specifically an Executive Order signed by the President regarding medical marijuana and cannabidiol (CBD) research. This regulation provides a comprehensive framework for improving medical marijuana and CBD research in the United States. The order directs the Attorney General to expedite rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act, recognizing its potential medical uses. It acknowledges that 40 states have medical marijuana programs and that significant medical evidence supports its use in treating conditions like chronic pain, anorexia, and chemotherapy-induced nausea. The regulation calls for developing research methods that utilize real-world evidence, creating guidance on hemp-derived cannabinoid product standards, and establishing a regulatory framework to improve patient and doctor understanding of medical marijuana and CBD. Key federal agencies including HHS, FDA, CMS, and NIH are tasked with developing research models and standards, with a particular focus on understanding long-term health effects, especially in vulnerable populations like adolescents and young adults. The order aims to bridge the current gap between widespread medical marijuana and CBD use and the scientific understanding of their risks and benefits, while ensuring patient safety and appropriate product regulation.